Takeda thinks that their anti-HIV monoclonal antibody drug, TAK-779, might work even better than Actemra (tocilizumab) for treating the cytokine storm of COVID-19 and other diseases: https://t.co/fdiCWXlwyu https://t.co/ZKs0hWwlj6 https://t.co/UP2m2dMqkK h
ARDS, a major cause of #COVID-19 mortality, affects over 0.7 billion cases. This study demonstrates TAK-779's efficacy in preventing virus-induced hyperinflammation, surpassing dexamethasone and tocilizumab. Daily biotech insights 👉🏼 @gathersight. https://
New Research: CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome https://t.co/PbfAwfQZEo #pharmacology